1. Introduction {#sec1}
===============

Traditional Chinese Medicine (TCM) prescriptions have played an important role in prevention and treatment of diseases for thousand years in some Asia countries such as China, Japan, and Korea. Several TCMs were usually combined together as a prescription which is the main form of TCMs to improve the therapeutic efficacy and reduce the possible adverse effect through synergistic action in clinic. Most of the TCM prescriptions were applied to treating some diseases from the ancient times and their therapeutic effects have been demonstrated and proved by broad clinical practice. Considering the effectiveness of the TCM prescriptions, it was necessary to perform more in-depth science research for clarifying material base of TCM prescriptions.

Buyanghuanwutang, one of the famous TCM prescriptions from the ancient medical book*Yi Lin Gai Cuo* written by Qingren Wang in Qing Dynasty, mainly records the theory "promoting blood circulation and removing blood stasis." Naoxintong capsule (NXTC) is a patent medicine designed on the base of Buyanghuanwutang. It has been widely used in China to treat cerebrovascular disease caused by deficiency of Qi and blood stasis such as hemiplegia and stroke. NXTC contains 11 plant medicines (*Astragali Radix* (Huangqi),*Paeoniae Radix Rubra* (Chishao),*Salviae miltiorrhizae Radix et Rhizoma* (Danshen), Persicae Semen (Taoren),*Angelicae Sinensis Radix* (Danggui),*Achyranthis bidentatae Radix* (Niuxi),*Chuanxiong Rhizoma* (Chuanxiong),*Spatholobi Stem* (Jixueteng),*Cinnamomi Ramulus* (Guizhi),*Carthami Flos* (Honghua) and*Mori Ramulus* (Sangzhi)), two resins (*Olibanum*(Ruxiang),*Myrrha*(Moyao)), and three animal medicines (*Scorpio*(Quanxie),*Pheretima* (Dilong), and*Hirudo* (Shuizhi)) \[[@B1]\]. As NXTC is a widely used patent medicine in clinic, there were many reports on modern pharmacological studies and clinical analysis. NXTC could protect brain tissue from ischemia-reperfusion injury through some different ways \[[@B2]--[@B5]\]. It also could cure cognitive dysfunctions and treat patients with vascular dementia and coronary heart disease \[[@B6], [@B7]\]. NXTC has beneficial effects on atherosclerosis treatment by reducing expression of iNOS mRNA and the NO level in the vessel wall \[[@B8]\]. It was demonstrated that NXTC protected H9c2 cardiomyoblasts from H~2~O~2~-induced oxidative injury by increasing antioxidant abilities, activating ERK~1/2~, and blocking Ca~2~^+^-dependent and mitochondria-mediated apoptosis \[[@B9]\]. NXTC protected against atherosclerosis through lipid-lowering and inhibiting dendritic cells maturation in mice model of atherosclerosis \[[@B10]\]. It could reduce the infarct size of acute myocardial infarction patients and promote the cerebral blood circulation and renovate cerebral damage in treating hypertensive cerebral hemorrhage after surgical management \[[@B11]\]. Furthermore, it was reported that NXTC can inhibit the development of diabetic retinopathy \[[@B12]\]. NXTC could obviously increase the effect on the catalytic activities of drug metabolising CYP2C19 enzyme \[[@B13]\]. All of these reports indicated that NXTC had many important pharmacological functions and excellent efficacy.

Pharmacokinetics of TCM could provide scientific evidence such as absorption, distribution, metabolism, excretion, and metabolism of chemical components contained in TCMs. It was well-known that chemical components were only absorbed into blood, reach a certain blood concentration, and exert pharmacological effects. Therefore, it was very useful to do pharmacokinetic study of multiple compounds of NXTC for exploring the active compounds. Considering its complicated compounds of TCM, it was needed to establish a suitable method for clarifying the relation of complicated compounds and clinical effect.

Ultrahigh-performance liquid chromatography (UHPLC) and HPLC-ESI/TOF have been published for quality control of NXTC \[[@B14], [@B15]\]. The characteristics of absorption of four components (ferulic acid, paeoniflorin, salvianolic acid B, and hydroxysafflor yellow A) from NXTC in intestines were studied by UHPLC methods \[[@B16]\]. However, none of them is involved in pharmacokinetic study of multiple compounds of NXTC among all methods mentioned above. To our knowledge, there were no pharmacokinetic studies about NXTC as a powerful analytical technique. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has gained much attention in bioanalytical analysis \[[@B17], [@B18]\], since it owned the advantages such as excellent specificity and sensitivity. The eleven typical compounds including paeoniflorin, ecdysterone, amygdalin, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside IV, formononetin, cryptotanshinone, and tanshinone IIA are usually selected as mainly ingredients of some TCM material prescribed in Chinese Pharmacopoeia. In our study, these 11 typical compounds were selected as markers. A specific and sensitive LC-MS/MS method was established and validated to simultaneously determine concentration of 11 compounds in rat plasma. The new method has been validated and successfully applied to the pharmacokinetic study of 5 typical compounds after oral administration of NXTC.

2. Experimental {#sec2}
===============

2.1. Material and Reagents {#sec2.1}
--------------------------

Methanol (Tianjin Concord Science Co. Ltd., Tianjin, China) and acetonitrile (Dikma Technologies Inc., USA) were of HPLC grade. Formic acid was purchased from Sigma-Aldrich (St. Louis, MO, USA). Deionized water was prepared with a Milli-Q Academic ultrapure water system (Millipore, Milford, MA, USA). All other reagents were of analytical grade (Tianjin Concord Science Co. Ltd., Tianjin, China). Standard references including paeoniflorin, ecdysterone, amygdalin, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside IV, formononetin, cryptotanshinone, tanshinone IIA, chlorogenic acid, geniposide, sennoside B, and puerarin were purchased from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China) and Must Bio-Technology Co., Ltd. (Chengdu, China). The NXTC was purchased from Shaanxi Buchang Pharmaceutical Co., Ltd. (Xi -an, China).

2.2. Preparation of Stock Solution, Calibration Samples, and Quality Control (QC) Samples {#sec2.2}
-----------------------------------------------------------------------------------------

Stock solutions of paeoniflorin, ecdysterone, amygdalin, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside IV, formononetin, cryptotanshinone, and tanshinone IIA were prepared separately in methanol to achieve a high concentration of 1.0 mg mL^−1^ and chlorogenic acid, geniposide, sennoside B, and puerarin were prepared as internal standards (ISs) with the same way to achieve a concentration of 100 ng mL^−1^. Appropriate volumes of the 11 standard solutions were mixed to obtain the working standard solution. All solutions were stored at 4°C.

A series of different concentrations of working solution were obtained by mixed appropriate volume of the standard solutions and diluting with methanol. Then calibration work solutions were prepared by adding 10 *μ*L of the series work standard solutions, 10 *μ*L IS and 10 *μ*L formic acid into 100 *μ*L blank rat plasma. The final concentrations of the series analytes were prepared ranging within 2.5--750 ng mL^−1^ for paeoniflorin, 5--1500 ng mL^−1^ for ecdysterone, 10--3000 ng mL^−1^ for amygdalin, salvianolic acid B, and astragaloside IV, 3--3000 ng mL^−1^ for mulberroside A and caffeic acid, 1.5--1500 ng mL^−1^ for ferulic acid, 0.075--75 ng mL^−1^ for formononetin and cryptotanshinone, 0.3--300 ng mL^−1^ for tanshinone IIA, respectively.

Quality control (QC) samples were prepared following the same sample preparation method described above at the concentrations of 7.5, 75, and 750 ng mL^−1^ for paeoniflorin, 15, 150, and 1500 ng mL^−1^ for ecdysterone and ferulic acid, 30, 300, and 3000 ng mL^−1^ for amygdalin, salvianolic acid B, mulberroside A, caffeic acid, and astragaloside IV, 0.75, 7.5, and 75 ng mL^−1^ for formononetin, cryptotanshinone, and 3, 30, and 300 ng mL^−1^ for tanshinone IIA, respectively. Calibration work solutions and QC samples were stored at 4°C until LC-MS/MS analysis.

2.3. LC-MS/MS Analysis {#sec2.3}
----------------------

The LC-MS/MS analysis was carried out on an Agilent 1200 system (Agilent Corporation, USA) coupled with an API 3200 triple quadrupole mass spectrometer with a Turbo Ion Spray Ionization (ESI) source (Concord, Ontario, Canada). The Agilent 1200 system consisted of a vacuum degasser (G1322A), a binary pump (G1312A), and a Hip-ALS autosampler (G13678). Chromatographic separation was performed on an Eclipse plus C18 column (4.6 × 100 mm, 1.8 *μ*m) with a security guard C~18~ column (2.1 mm × 12.5 mm, 5 *μ*m) (Agilent, USA). The mobile phases consisted of acetonitrile (A) and formic acid aqueous solution (B). The linear gradient was 30% A-30% A (0--10 min); 30%--80% A (10--15 min); 80%--95% A (15--20 min); 95%-95% A (20--30 min). Reequilibration time after gradient elution was 5 min. The column temperature was maintained at 25°C and the flow rate was set at 0.300 mL min^−1^. ESI-MS spectra were acquired in both negative and positive ion multiple reaction monitoring (MRM) mode. The conditions of source and MRM parameters were shown in [Table 1](#tab1){ref-type="table"}. Data collection and peak calculations were performed by Analyst 1.4.2 software (AB MDS Sciex).

2.4. Preparation of Sample {#sec2.4}
--------------------------

The ISs solution (10 *μ*L) and formic acid (10 *μ*L) were added to plasma samples (100 *μ*L). Acetonitrile (370 *μ*L) was used to precipitate protein. The mixed solution was swirled for 1 min and then centrifuged at 14000 rpm for 10 min. The supernatant fluid was collected and then evaporated to dryness with a stream of N~2~ gas in a 40°C water bath. The residue was reconstituted in 100 *μ*L methanol, swirled for 1 min. The sample was centrifuged at 14000 rpm for 10 min. 10 *μ*L of the supernatant was injected into the LC-MS/MS system for analysis.

2.5. Method Validation {#sec2.5}
----------------------

The method was validated in terms of specificity, lower limit of quantification (LLOQ), accuracy and precision, extraction recovery, matrix effect, and stability following the guidelines for bioanalytical method validation issued by the FDA Center for Drug Evaluation and Research.

### 2.5.1. Specificity {#sec2.5.1}

The specificity of the method was investigated by comparing chromatograms of blank plasmas obtained from six different rats, with those obtained from corresponding standard plasma samples spiked with eleven analytes and ISs, and real plasma sample at 0.5 h after oral administration of NXTC.

### 2.5.2. Linearity and LLOQ {#sec2.5.2}

The linearity was carried out by analyzing a series of calibration work solutions in duplicate over 3 consecutive days. The calibration curve was individually determined by plotting the peak area ratio of each analyte/IS (*y*) versus the nominal concentration (*x*) of each analyte. The linearity was analyzed by weighted (1/*x*^2^) least squares linear regression. The lower limit of quantification (LLOQ) defined as the signal-to-noise ratio (S/N) was higher than 5 and the relative standard deviation (RSD) was within 20%.

### 2.5.3. Accuracy and Precision {#sec2.5.3}

The intraday precision and accuracy were assessed by determining LLOQ and QC samples at low, medium, and high concentration (*n* = 6) of the same day. The interday accuracy and precision were tested by performing the procedure once a day for 3 consecutive days to determine interday precision along with the standard calibration curve. The intraday and interday precisions were evaluated by using the relative standard deviations (RSDs) and the accuracy was assessed by calculating the percentage of measured concentration to the nominal concentration. Acceptance criteria of each concentration level from the nominal concentration should be less than ±15.0% and less than ±20.0% at LLOQs.

### 2.5.4. Recovery and Matrix Effect {#sec2.5.4}

The recovery of 11 analytes at three concentration levels and ISs were tested by comparing the peak areas of the analytes in extracted samples with those of the postextracted spiked samples. The matrix effect of the analytes and ISs had been detected by comparing the peak areas of the analytes in postextracted spiked samples with those of corresponding standard solutions at three concentration levels. Both the recovery and matrix effect were measured in six replicates.

### 2.5.5. Stability {#sec2.5.5}

The stability tests were performed to determine the analytes at room temperature for 24 h, stored at −20°C for a month and under three freeze-thaw cycles. All stability studies were performed six times at three level QC samples.

2.6. Determination of 11 Compounds in NXTC {#sec2.6}
------------------------------------------

The contents of paeoniflorin, ecdysterone, amygdalin, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside IV, formononetin, cryptotanshinone, and tanshinone IIA in NXTC were quantitatively determined to calculate the administration dosage to rats. Take appropriate NXTC dissolved in methanol and ultrasonic extracted for 20 min and then centrifuged at 14,000 ×g for 10 min. 10 *μ*L of the filtrate was injected into LC-MS/MS for quantitative analysis. The contents of paeoniflorin, ecdysterone, amygdalin, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside IV, formononetin, cryptotanshinone, and tanshinone IIA were determined as 1663.3, 45.7, 2203.3, 79.0, 14.2, 107.3, 685.3, 70.0, 78.4, 97.2, and 154.0 *μ*g/g, respectively.

2.7. Pharmacokinetic Study {#sec2.7}
--------------------------

Twenty Male Sprague-Dawley rats (220--250) g were obtained from Shan Chuanhong experimental animals Technology Co., Ltd. (Beijing, China). Rats had been bred in a breeding room (12 h dark-light cycle; temperature was 23°C ± 2°C and humidity was 50 ± 5%) and fed standard laboratory food and water for a week to acclimatization. The animal experiment was conducted according to the Institute\'s Guide for the Care and Use of Laboratory Animals of Tianjin University of Traditional Chinese Medicine. Rats were fasted for 12 h with free access to water before the experiment. NXTC extracts were orally administrated to ten rats at single time dose (0.5 g kg^−1^) and to ten rats at triple doses (1.5 g kg^−1^). The blood samples were collected at 5, 10, 15, 30, 45, 60, 90, 120, 240, 480, 720, and 1440 min after oral administration. Blood samples (200 *μ*L) were collected from the vein of the eye sockets into heparinized tubes after the rats were anesthetized with ethyl ether. The samples were immediately centrifuged at 7,000 rpm, 10°C for 10 min. Then the plasma samples obtained were stored at −20°C.

2.8. Data Analysis {#sec2.8}
------------------

Some pharmacokinetic parameters were calculated by DAS1.0 software (Drug and Statistics 1.0, Medical College of Wannan, China). An appropriate model was employed to calculate the following parameters: area under the plasma concentration versus time curve from zero to last sampling time (AUC~0→24 h~) and infinity (AUC~0→*∞*~) and mean retention time from zero to last sampling time (MRT~0→24 h~). The maximum drug concentration in plasma (*C*~max~) and the time to reach maximum drug concentration (*T*~max~) were directly obtained from individual plasma concentration-time data observed. All data were shown as average value ± standard deviation.

3. Results and Discussion {#sec3}
=========================

3.1. Method Development {#sec3.1}
-----------------------

### 3.1.1. Optimization of Mass Spectrometry {#sec3.1.1}

In order to achieve maximum responses of all analytes, the MS conditions had been optimized by infusing their standard solution to the mass spectrometer. Both positive and negative ionization modes were optimized and the full-scan mass spectra showed that the signals of cryptotanshinone, tanshinone IIA, and astragaloside IV in positive ion mode were higher than those in negative ion mode while the other analytes show higher values in negative ion mode than those in positive ion mode. Finally, the source parameters were optimized to achieve the maximum abundance of the molecular ions of the compounds. All results were listed in [Table 1](#tab1){ref-type="table"}. Geniposide, chlorogenic acid, puerarin, and sennoside B were selected as internal standards to determine glycoside (paeoniflorin, ecdysterone, amygdalin, mulberroside A, and astragaloside IV), phenolic acids (caffeic acid, ferulic acid, and salvianolic acid B), flavonoids (formononetin), and tanshinone (cryptotanshinone and tanshinone IIA), respectively.

### 3.1.2. Optimization of Chromatography Condition {#sec3.1.2}

To achieve good peak symmetry and sufficient ionization response for each analyte, a gradient mobile phase system with acetonitrile-water was optimized. It was found that ferulic acid, caffeic acid, and salvianolic acid B have good peak symmetry when 0.1% formic acid was added in the water. Thus, acetonitrile-water containing 0.1% formic acid system was selected as mobile phase.

### 3.1.3. Optimization of Extraction Conditions {#sec3.1.3}

The extraction conditions were focused on decreasing the matrix effect and increasing extraction recovery. In this study, two commonly used blood sample treatment methods including liquid-liquid extraction (LLE) with ethyl acetate and protein precipitation (PPT) with acetonitrile were evaluated. It was found that the extraction recovery of LLE with ethyl acetate was very low due to the complicated polarity of the analytes in this case. The PPT with acetonitrile showed higher extraction efficiency and lower noise level. Therefore, protein precipitation (PPT) with acetonitrile was selected to prepare the samples.

3.2. Method Validation {#sec3.2}
----------------------

### 3.2.1. Specificity {#sec3.2.1}

Typical chromatograms of blank sample, standard sample (LLOQ), and plasma samples are shown in [Figure 1](#fig1){ref-type="fig"}, respectively. The analytes were well separated and no endogenous interference was observed at retention time of paeoniflorin (4.47 min), ecdysterone (4.48 min), amygdalin (4.49 min), mulberroside A (4.53 min), caffeic acid (5.28 min), ferulic acid (min 7.32), salvianolic acid B (8.92 min), astragaloside IV (18.79 min), formononetin (20.43 min), cryptotanshinone (25.64 min), tanshinone IIA (27.53 min), and four ISs such as sennoside B (4.43 min), puerarin (4.44 min), chlorogenic acid (4.45 min), and geniposide (4.47 min) as shown in [Figure 1](#fig1){ref-type="fig"}.

### 3.2.2. Calibration Curve and Lower Limits of Quantification {#sec3.2.2}

The standard calibration curves for spiked rat plasma containing paeoniflorin, ecdysterone, amygdalin, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside IV, formononetin, cryptotanshinone, and tanshinone IIA were linear within the concentration rang of 2.5--750 ng mL^−1^, 5--1500 ng mL^−1^ 10--3000 ng mL^−1^, 3--3000 ng mL^−1^, 3--3000 ng mL^−1^, 1.5--1500 ng mL^−1^, 10--3000 ng mL^−1^, 10--3000 ng mL^−1^, 0.075--75 ng mL^−1^, 0.075--75 ng mL^−1^, and 0.3--300 ng mL^−1^ and the regression equations are as shown in [Table 2](#tab2){ref-type="table"}. The lower limit of quantifications (LLOQs) for determination of 11 compounds in plasma were 2.5 ng mL^−1^, 5 ng mL^−1^, 10 ng mL^−1^, 3 ng mL^−1^, 3 ng mL^−1^, 1.5 ng mL^−1^, 10 ng mL^−1^, 10 ng mL^−1^, 0.075 ng mL^−1^, 0.075 ng mL^−1^ and 0.3 ng mL^−1^, respectively. The accuracy of LLOQ was from 98.3% to 105% and the relative standard deviation (RSD) (*n* = 6) was less than 14%. All data is listed in [Table 2](#tab2){ref-type="table"}.

### 3.2.3. Precision and Accuracy {#sec3.2.3}

The precision and accuracy of the method are summarized in [Table 3](#tab3){ref-type="table"}. The assay values for both intra- and interday were found to be within the accepted variable limits. The RSD% of intra- and interday was below 15%, and the accuracy was within the range from 85 to 114%. The results demonstrated that the method was accurate and reproducible for determination of all analytes in rat plasma.

### 3.2.4. Extraction Recovery and Matrix Effect {#sec3.2.4}

The extraction recoveries and matrix effects of the method are summarized in [Table 4](#tab4){ref-type="table"}. The extraction recoveries of all analytes ranged from 60% to 107% at three-level QC samples and their RSDs were less than 15%. The matrix effects of all analytes except for paeoniflorin ranged from 85.2% to 115% for three-level QC samples and their RSDs were less than 15%. Although the matrix effects of paeoniflorin were from 127% to 152%, its RSDs were less than 15%. It was concluded that protein precipitation with acetonitrile proved to be precise and could be used to extract the analytes from the plasma sample.

### 3.2.5. Stability {#sec3.2.5}

The stability of all the analytes under various conditions is presented in [Table 5](#tab5){ref-type="table"}. It was found that the these analytes were stable in rat plasma after room temperature for 24 h, stored at −20°C for one month, under three freeze-thaw cycles. The above results demonstrate that the developed HPLC-MS/MS method could be used to determine all these analytes in rat plasma.

3.3. Assaying the Dosage of Oral Administration of 11 Components {#sec3.3}
----------------------------------------------------------------

The contents of 11 components in NXTC capsule were determined by the HPLC-MS/MS method. The results showed that the oral dose of paeoniflorin, ecdysterone, amygdalin, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside IV, formononetin, cryptotanshinone, and tanshinone IIA was 831.7 *μ*g kg^−1^, 22.9 *μ*g kg^−1^, 1101.7 *μ*g kg^−1^, 39.5 *μ*g kg^−1^, 7.1 *μ*g kg^−1^, 53.7 *μ*g kg^−1^, 342.7 *μ*g kg^−1^, 35.0 *μ*g kg^−1^, 39.2 *μ*g kg^−1^, 48.6 *μ*g kg^−1^, and 77 *μ*g kg^−1^ after oral administration of NXTC at doses of 0.5 g kg^−1^, respectively.

3.4. Pharmacokinetic Study {#sec3.4}
--------------------------

The developed HPLC-MS/MS method was successfully used to determine the plasma concentrations of 11 components after oral administration of NXTC at doses of 0.5 g kg^−1^ and 1.5 g kg^−1^, respectively. The results showed that 5 components (caffeic acid, ferulic acid, formononetin, cryptotanshinone, and tanshinone IIA) could be detected in rat plasma after oral administration of NXTC while the other 6 components (paeoniflorin, ecdysterone, amygdalin, mulberroside A, salvianolic acid B, and astragaloside IV) were not detected at the present LLOQ level. The result indicated that some more sensitive methods would be established and validated to focus on the mechanism of absorption and metabolism of these six components. However, the LLOQs of the new method were sufficient to characterize the pharmacokinetics of the other 5 components (caffeic acid, ferulic acid, formononetin, cryptotanshinone, and tanshinone IIA) in rats. The partial main pharmacokinetic parameters of caffeic acid, ferulic acid, formononetin, cryptotanshinone, and tanshinone IIA in rats are shown in [Table 6](#tab6){ref-type="table"}. The mean plasma concentration-time profiles of caffeic acid, ferulic acid, formononetin, cryptotanshinone, and tanshinone IIA are shown in [Figure 2](#fig2){ref-type="fig"}. It was observed that *T*~max~ of 3 components (caffeic acid, ferulic acid, and formononetin) were less than 1 h, which implied that they were rapidly absorbed in rat plasma after oral administration of NXTC at doses of 0.5 g kg^−1^ and 1.5 g kg^−1^. Ferulic acid, as a hydroxycinnamic acid, is a well-known antioxidant compound and has the cardiovascular protection function \[[@B19]\]. It is used for treating age-related diseases such as neurodegenerative disorders and cardiovascular disease \[[@B20]\]. The pharmacokinetic results indicated that the mean *T*~max~ after single dose administration of NXT capsule was 0.17 h. It was six times higher than the mean *T*~max~ of 0.03 h after a single oral administration of ferulic acid \[[@B21]\], which implies other components in NXTC might affect the absorption of ferulic acid. All *C*~max~ and AUC~(0--24 h)~ values of 5 components (caffeic acid, ferulic acid, formononetin, cryptotanshinone, and tanshinone IIA) after oral administration of NXT capsule at triple doses of 1.5 g kg^−1^ were higher than those after oral administration at normal doses of 0.5 g kg^−1^. It was indicated that the absorptions of these 5 components in vivo were promoted with the increase of the oral dose of administration of NXTC. Cryptotanshinone and tanshinone IIA have attracted particular attention from medicinal chemists and clinicians due to their diverse biological activities, such as antihypertensive effect and antithrombus and antiplatelet aggregation activities \[[@B22], [@B23]\].*T*~1/2~ values of cryptotanshinone (17.8 ± 17.1 h) and tanshinone IIA (17.8 ± 17.1 h) indicated that the action time of both cryptotanshinone and tanshinone IIA were significantly longer in body than the other three components. As shown in [Figure 2](#fig2){ref-type="fig"}, two plasma concentration peaks were observed in the mean plasma concentration curves profiles of cryptotanshinone and tanshinone IIA, which was consistent with results from previous studies \[[@B24]\]. Caffeic acid has very excellent antioxidant and antiviral activity \[[@B25]\]. From [Table 6](#tab6){ref-type="table"}, it was found that values of *T*~max~ and*T*~1/2~ of caffeic acid and ferulic acid were much closer, demonstrating that they have similar absorption and elimination rate. The *C*~max~ values were 15.24 ± 3.08 ng mL^−1^ and 12.07 ± 4.61 ng mL^−1^ and values of AUC~(0--24 h)~ were 25.99 ± 18.62 ng mL^-1 ^h^−1^and 8.33 ± 3.87 ng mL^−1^ h^−1^ for caffeic acid and ferulic acid at triple doses, respectively. The results were not correspondent with their dose administered to the rats (7.1 *μ*g kg^−1^ caffeic acid and 53.7 *μ*g kg^−1^ ferulic acid). The possible reason may be that some of the caffeic acid detected in rat plasma was the metabolites of the components in NXTC. It was reported that the medicinal herbs containing formononetin often have been used to treat cardiovascular diseases for a long time \[[@B26]\]. In the present studies, *C*~max~ of formononetin was less than 1 ng mL^−1^. The AUC~(0--24 h)~ values were lower than 1 ng mL^−1^. These showed that formononetin might still be a mainly active ingredient that we can detect in rat plasma. Based on the above results, the newly established LC-MS/MS method was sufficiently sensitive for the determination of multiple components in rat plasma and was suitable to simultaneously evaluate the pharmacokinetic properties of the multiple bioactive components after oral administration of NXTC.

4. Conclusion {#sec4}
=============

A rapid, reliable, and sensitive HPLC-MS/MS method was validated and optimized for quantitative analysis of paeoniflorin, ecdysterone, amygdalin, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside IV, formononetin, cryptotanshinone, and tanshinone IIA in rat plasma. To our knowledge, this is the first time to evaluate the pharmacokinetics of NXTC after oral administration. It could be useful to the clinical application and for the quality control of the medicine. The pharmacokinetic parameters obtained from this study and the validated method would be useful in clinical applications of TCM preparations of Naoxintong capsule.
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![The chromatograms of the analytes in rat plasma: blank plasma (a), blank rat plasma spiked with standard compounds (b), and plasma samples taken from rats 30 min after oral administration of traditional Chinese medicinal preparation of Naoxintong capsule (c).](ECAM2017-9057238.001){#fig1}

![The mean plasma concentration-time profiles of caffeic acid, ferulic acid, formononetin, cryptotanshinone, and tanshinone IIA after oral administration of Naoxintong capsule at doses of 0.5 g kg^−1^ and 1.5 g kg^−1^ (*n* = 10).](ECAM2017-9057238.002){#fig2}

###### 

Source and MRM parameters of the eleven compounds and four ISs.

  Compounds            Parameter                                                                  
  -------------------- ----------- --- ------- ----- ---- ---- ------- ------- ----- ------ ----- ------
  Paeoniflorin         20          8   −4500   500   30   30   478.6   121.1   −45   −4     −30   −1
  Ecdysterone          20          8   −4500   500   30   30   478.9   159.0   −60   −10    −37   −1
  Amygdalin            20          8   −4500   500   30   30   455.8   322.8   −50   −4.5   −20   −22
  Mulberroside A       20          8   −4500   500   30   30   567.0   242.6   −60   −10    −38   −16
  Caffeic acid         20          8   −4500   500   30   30   178.9   134.9   −35   −3.5   −24   −0.5
  Ferulic acid         20          8   −4500   500   30   30   192.8   133.9   −31   −4     −23   −1
  Salvianolic acid B   20          8   −4500   500   30   30   716.5   518.5   −55   −4.5   −25   −40
  astragaloside IV     10          8   5000    500   40   30   807.0   807.0   140   10     50    55
  Formononetin         20          8   −4500   500   30   30   267.0   251.8   −60   −2     −27   −16
  Cryptotanshinone     10          8   5000    500   40   30   297.0   254.2   50    9      35    15
  Tanshinone IIA       10          8   5000    500   40   30   295.2   277.1   58    10     27    21
  Geniposide           20          8   −4500   500   30   30   387.0   224.7   −40   −9     −15   −15
  Sennoside B          20          8   −4500   500   30   30   860.6   385.9   −87   −10    −60   −2
  Puerarin             20          8   −4500   500   30   30   414.8   266.9   −50   −9     −46   −2
  Chlorogenic acid     20          8   −4500   500   30   30   352.8   190.9   −33   −4     −32   −2

###### 

Linear regression data, LLODs, and accuracy for the eleven compounds.

  Compounds            Regression equation          *r*      Linearity range (ng*∗*mL^−1^)   LLOD (ng*∗*mL^−1^)   Accuracy (%)   RSD (%)
  -------------------- ---------------------------- -------- ------------------------------- -------------------- -------------- ---------
  Paeoniflorin         *Y* = 0.0124*x* + 0.0522     0.9997   2.5--750                        2.5                  99.5           13
  Ecdysterone          *Y* = 0.0128*x* − 0.000782   0.9985   5--1500                         5                    100            6.3
  Amygdalin            *Y* = 0.016*x* + 0.1114      0.9976   10--3000                        10                   99.2           12
  Mulberroside A       *Y* = 0.0217*x* − 0.0373     0.9910   3--3000                         3                    92.3           14
  Caffeic acid         *Y* = 0.083*x* + 1.12        0.9993   3--3000                         3                    100            7.4
  Ferulic acid         *Y* = 0.00894*x* + 0.0224    0.9962   1.5--1500                       1.5                  91.4           5.4
  Salvianolic acid B   *Y* = 0.00541*x* − 0.0233    0.9972   10--3000                        10                   105            7.8
  Astragaloside IV     *Y* = 0.3*x* − 2.28          0.9982   10--3000                        10                   99.7           6.9
  Formononetin         *Y* = 0.00216*x* + 0.00183   0.9958   0.075--75                       0.075                99.2           4.4
  Cryptotanshinone     *Y* = 0.0589*x* − 0.28       0.9916   0.075--75                       0.075                98.3           4.4
  Tanshinone IIA       *Y* = 0.0387*x* − 0.0776     0.9975   0.3--300                        0.3                  101            3.5

###### 

Intraday and interday accuracy and precision of eleven compounds (*n* = 6).

  Compounds            Concentration (ng*∗*mL^−1^)   Intraday   Interday          
  -------------------- ----------------------------- ---------- ---------- ------ -----
  Paeoniflorin         7.5                           93.0       14         95.7   2.5
  75                   101                           8.7        102        3.8    
  750                  96.6                          6.3        101        1.2    
  Ecdysterone          15                            111        8.4        102    2.5
  150                  106                           12         99.6       3.0    
  1500                 101                           6.7        97.7       5.2    
  Amygdalin            30                            98         10         101    1.9
  300                  100                           11         99.1       3.5    
  3000                 102                           11         101        0.8    
  Mulberroside A       30                            88         13         96.6   2.4
  300                  104                           12         90.9       8.3    
  3000                 114                           3          98.8       12     
  Caffeic acid         30                            103        8.5        102    3.0
  300                  85                            9.4        95.2       10     
  3000                 103                           7.8        95.0       4.2    
  Ferulic acid         15                            106        10         98.0   10
  150                  111                           7.7        102        7.0    
  1500                 113                           2.9        106        4.5    
  Salvianolic acid B   30                            103        10         97.2   9.4
  300                  109                           6          102        4.1    
  3000                 100                           12         106        9.0    
  Astragaloside IV     30                            90.3       14         94.7   4.9
  300                  107                           10         102        8.2    
  3000                 103                           8.4        101        4.8    
  Formononetin         0.75                          107        3.4        100    1.1
  7.5                  105                           14         101        8.2    
  75                   114                           7.3        101        1.7    
  Cryptotanshinone     3                             90         9.4        97.9   3.2
  30                   97.4                          14         101        13     
  300                  103                           11         103        5.5    
  Tanshinone IIA       0.75                          104        6.1        100    2.4
  7.5                  101                           15         98.7       5.8    
  75                   104                           13         97.5       4.4    

###### 

Recoveries and matrix effects of eleven compounds (*n* = 6).

  Compounds            Concentration (ng*∗*mL^−1^)   Recovery   Matrix effect          
  -------------------- ----------------------------- ---------- --------------- ------ -----
  Paeoniflorin         7.5                           100        7.8             152    12
  75                   96.6                          12         127             11     
  750                  83.6                          12         146             12     
  Ecdysterone          15                            98.9       6.2             80.0   12
  150                  83.6                          9.6        95.8            11     
  1500                 104                           7.0        110             13     
  Amygdalin            30                            107        12              78.0   4.8
  300                  90.5                          7.8        82.6            7.8    
  3000                 87.2                          13         75.7            11     
  Mulberroside A       30                            78.7       4.9             84.3   5.6
  300                  92.0                          15         76.0            14     
  3000                 76.6                          5.9        73.7            8.2    
  Caffeic acid         30                            98.2       7.1             96.4   3.6
  300                  81.8                          12         107             9.9    
  3000                 88.7                          6.3        109             7.5    
  Ferulic acid         15                            91.6       6.5             101    3.7
  150                  79.6                          6.8        89.5            4.4    
  1500                 93.2                          7.5        92.6            8.9    
  Salvianolic acid B   30                            82.6       14              105    11
  300                  62.7                          10         82.7            6.2    
  3000                 81.2                          8.5        76.0            9.7    
  Astragaloside IV     30                            91.0       9.0             109    9.3
  300                  95.2                          4.7        109             14     
  3000                 97.1                          13         115             3.0    
  Formononetin         0.75                          87.9       7.5             98.5   4.2
  7.5                  103                           12         87.7            9.3    
  75                   99.7                          13         106             13     
  Cryptotanshinone     3                             97.0       14              75.3   12
  30                   76.2                          8.2        89.0            4.6    
  300                  76.0                          14         79.0            5.5    
  Tanshinone IIA       0.75                          99.6       9.3             92.0   5.2
  7.5                  60.0                          14         96.0            8.4    
  75                   81.5                          6.6        90.0            11     

###### 

24 h storage at room temperature stability, three freeze-thaw cycles stability and long-term stability of eleven compounds (*n* = 6).

  Compound             Concentration (ng mL^−1^)   Freeze-thaw cycles   At −20°C for 1 weeks   Autosampler for 24 h                 
  -------------------- --------------------------- -------------------- ---------------------- ---------------------- ------ ------ -----
  Paeoniflorin         7.5                         93.7                 14                     101                    8.8    95.8   15
  75                   88.0                        8.6                  85.8                   9.5                    97.4   6.4    
  750                  106                         5.0                  96.5                   13                     89.9   11     
  Ecdysterone          15                          97.1                 11                     102                    11     94.2   8.4
  150                  95.5                        14                   107                    11                     102    7.0    
  1500                 95.0                        8.0                  103                    12                     93.1   6.2    
  Amygdalin            30                          87.0                 10                     93.0                   7.2    98.1   9.0
  300                  87.9                        12                   105                    14                     94.2   15     
  3000                 103                         10                   94.1                   13                     92.6   12     
  Mulberroside A       30                          104                  11                     112                    12     86.6   10
  300                  94.4                        14                   106                    5.7                    87.7   9.9    
  3000                 96.5                        9.9                  97.2                   13                     95.3   9.3    
  Caffeic acid         30                          106                  8.5                    95.8                   13     103    8.9
  300                  85.6                        14                   101                    11                     89.9   12     
  3000                 89.2                        3.5                  90.5                   11                     85.2   7.7    
  Ferulic acid         15                          111                  11                     105                    9.7    107    12
  150                  108                         11                   111                    11                     93.2   8.7    
  1500                 99.6                        4.1                  106                    7.5                    95.0   7.7    
  Salvianolic acid B   30                          97.1                 11                     113                    13     91.7   6.4
  300                  105                         8.8                  92.6                   9.4                    99.9   12     
  3000                 101                         12                   100                    13                     108    8.5    
  Astragaloside IV     30                          111                  4.7                    113                    6.7    86.3   10
  300                  103                         4.1                  108                    8.8                    101    12     
  3000                 95.4                        10                   97.4                   14                     96.1   14     
  Formononetin         0.75                        94.5                 6.2                    111                    8.6    102    13
  7.5                  89.9                        12                   88.9                   6.6                    111    12     
  75                   90.0                        9.0                  106                    1.8                    108    8.1    
  Cryptotanshinone     3                           104                  12                     112                    8.7    87.2   13
  30                   106                         10                   93.2                   8.5                    85.2   12     
  300                  107                         9.0                  109                    11                     87.5   12     
  Tanshinone IIA       0.75                        99.0                 4.9                    93.0                   10     88.4   12
  7.5                  114                         9.1                  105                    14                     94.9   9.0    
  75                   106                         10                   94.1                   15                     93.6   11     

###### 

Pharmacokinetic parameters of five compounds in rat plasma after oral administration of single dose and triple dose of NXT capsule. (*n* = 10, mean ± SD).

  Analytes                     Caffeic acid    Ferulic acid    Formononetin   Cryptotanshinone   Tanshinone IIA                                                           
  ---------------------------- --------------- --------------- -------------- ------------------ ---------------- ------------- ------------- ------------- ------------- -------------
  *T* ~max~ (h)                0.18 ± 0.03     0.20 ± 0.04     0.17 ± 0.00    0.19 ± 0.04        0.49 ± 0.33      0.38 ± 0.25   0.51 ± 0.40   0.60 ± 0.20   0.54 ± 0.29   3.17 ± 3.75
  *C* ~max~ (ng/mL)            9.80 ± 4.40     15.24 ± 3.08    10.93 ± 4.67   12.07 ± 4.61       0.11 ± 0.05      0.37 ± 0.32   0.61 ± 0.23   2.78 ± 2.52   1.61 ± 1.11   4.18 ± 3.34
  *T* ~1/2~ (h)                0.83 ± 0.33     0.70 ± 0.35     0.20 ± 0.19    0.42 ± 0.15        2.96 ± 5.61      1.42 ± 0.69   2.93 ± 3.89   17.8 ± 17.1   11.4 ± 15.8   13.2 ± 10.4
  AUC~(0--24 h)~ (ng/mL*∗*h)   11.68 ± 9.60    25.99 ± 18.62   3.20 ± 1.55    8.33 ± 3.87        0.08 ± 0.05      1.47 ± 1.82   1.49 ± 0.76   24.8 ± 27.9   8.15 ± 4.85   35.4 ± 42.2
  AUC~(0--*∞*)~ (ng/mL*∗*h)    19.57 ± 21.12   28.52 ± 20.01   4.19 ± 2.30    14.4 ± 12.8        0.15 ± 0.09      3.06 ± 3.07   4.72 ± 5.99   55.2 ± 59.8   27.7 ± 36.2   83.0 ± 81.0
  MRT~(0--24 h)~ (h)           1.33 ± 1.19     2.03 ± 1.43     0.28 ± 0.10    0.81 ± 0.38        0.56 ± 0.23      5.16 ± 3.68   3.06 ± 1.47   7.37 ± 3.95   5.48 ± 1.66   5.75 ± 3.36
  MRT~(0--*∞*)~ (h)            4.02 ± 4.96     2.72 ± 1.82     0.48 ± 0.33    3.80 ± 6.11        1.67 ± 1.53      25.9 ± 31.8   20.7 ± 27.7   19.0 ± 17.5   26.8 ± 31.5   27.2 ± 20.6

[^1]: Academic Editor: Nunziatina De Tommasi
